Search

everythinglearnresearchcommunity

for

Search:↓

TGPC plus CGT is effective and safe for treating severe alopecia areata in children.

New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.

Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.

Leflunomide and anthralin may effectively treat severe alopecia areata.

The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.

Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.

Ruxolitinib treatment may cause eyelash growth.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Restoring immune privilege in hair follicles could help treat certain types of hair loss.

Oxidative stress may contribute to hair loss in alopecia areata and antioxidants could potentially help as a treatment.

New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

OCT can detect hidden hair follicles in alopecia areata, indicating potential hair regrowth.

The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

A unique case showed a rare combination of two types of lichen planus on the face.

Different types of alopecia cause hair loss due to immune system issues, with some allowing regrowth and others causing permanent loss.

Vitiligo is influenced by genetics and environment, and combining these factors can improve early detection and prevention.

Small extracellular vesicles from stem and immune cells show promise for treating various diseases but face challenges in clinical use.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.

A gene variant causes patched hair loss in mice, similar to alopecia areata in humans.

Obesity negatively affects the endometrium, leading to higher miscarriage risk and impaired cell function.

Notch1 helps skin heal by attracting cells that aid repair.

Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.